Three hybridomas (PI P3, D7 and 60.5) producing monoclonal antibodies (mAbs) against Bordetella pertussis lipopolysaccharide (LPS) were established. All reacted with the LPS from a typical, vaccine strain of B. pertussis (1414), but not with that of a variant strain (A100). Two of these mAbs (PIP3 and 60.5) cross-reacted with a B. bronchiseptica LPS; only one (PlP3) reacted with a B. parapertussis LPS. ELISA reactivities with intact LPSs, and defined partial structures covalently linked to bovine serum albumin, were compared. mAb 60.5 bound to the terminal region of a distal trisaccharide consisting of Nacetylated amino sugars. D7 reacted with a substructure which can be modified in the B. parapertussis and B. bronchiseptica LPSs by addition of a polymeric O-chain. P I P3 bound to a nonacetylated glucosamine substituted with L-glycero-b-manno-heptose, present in the 'core' of the B. pertussis LPS. These mAbs may be useful for rapid typing of Bordetella in clinical isolates.
INTRODUCTION
Bordetella pertassis, the aetiological agent of whooping cough, expresses several antigenic proteins (pertussis toxin, adenylate cyclase, filamentous haemagglutinin) and, like all other Gram-negative bacteria, an ' endotoxin' which is actually a family of structurally related lipopolysaccharides (LPS). We established previously the existence of two types of variations in preparations of B. pertaxsir LPSs : one is due to the presence or absence of a phosphate group on a 3-deoxy-~-manno-2-octulosonic acid (Kdo) unit in the 'core' region (Le Dur et a/., 1980) , and the other is due to the presence or absence of a distal trisaccharide (Caroff e t al., 1990) . The latter finding explained the presence of two bands (designated A and B) in silver-stained SDS-PAGE of B. pertassis cell lysates (Peppler, 1984) . The observation that LPSs from B.
pertassis (Ackers & Dolby, 1972; Mountzouros et al., 1992) and from other bacteria (Terashima e t al., 1991) can elicit the production of protective antibodies, and the recent recrudescence of whooping cough in several developed countries, prompted us to produce anti-LPS monoclonal antibodies (mAbs) able to detect antigenic modifications in LPSs from variant B. pertassis strains, or from related Bordetella species (B. parapertassis, B. bronchiseptica) .
The production of mAbs to B. pertzmis LPSs has been reported by various authors (Mountzouros e t al., 1992; Frank & Parker, 1984 ; Gustafsson e t al., 1988; Li et al., 1988; Archambault e t al., 1991; Martin e t al., 1992) .
However, the characterization of the epitopes recognized by these mAbs was hampered by the absence of structural data on the antigens used. Our structural studies (Chaby & Caroff, 1988 ; Lebbar e t al., 1994 ; Di Fabio e t al., 1992) of different Bordetella LPSs allowed us to re-examine this problem. In this paper we describe the production of mAbs that we used to characterize three antigenic epitopes of B. pertzlssis LPSs. These mAbs may be useful for the rapid screening and typing of clinical isolates. anti-mouse H chain of different classes and subclasses, and the peroxidase substrates o-phenylenediamine dihydrochloride and 3,3'-diaminobenzidine were from Sigma. Polyisobutyl rnethacrylate was from Aldrich, gelatin from Rousselot Kuhlmann, and polyethylene glycol 1500 from Boehringer.
METHODS
Lipopolysaccharides. The B. perttlssis LPSs from the vaccine strain 1414, and from the variant strain A100, were isolated by the phenol/water extraction procedure, and purified as described previously (Le Dur et al., 1980; (Johnson & Perry, 1976) . The putative structures of these four LPSs , based on previously published (Chaby & Caroff, 1988; Lebbar etal., 1994; Di Fabio etal., '1992) or as yet unpublished studies (M. Caroff, D. Karibian, H. Zarrouk, J. C. Richards and M. B. Perry), are indicated in Fig. 1 .
Analyses.
The heptose content of the preparations was determined by quantitative estimation of heptitol acetate by GLC, after acid hydrolysis (2 M HC1,2 h, 100 "C) of the preparations, further reduction (1 M NaBH,, 4 h, 20 "C) of the sugars, and peracetylation of their alditols. Methylations, acetylations and GLC analyses (25 m x 0.32 mm capillary column coated with a BP 10 bonded phase) were carried out as described previously (Caroff e t al., 1990) .
Cleavage of LPSs with nitrous acid. The LPSs from the B. pertussis strains 1414 (LPS Bp1414) and A100 (LPS BpA100) were incubated (5 g 1-' ) for 4 h at 20 OC in a freshly prepared mixture of water/5 YO (w/v) sodium nitrite/30 Yo (v/v) acetic acid (1 : 1 : 1, by vol.), as described previously (Caroff etal., 1990 ; Deprun e t a/., 1993). The suspensions were ultracentrifuged (200 000 g for 2 h) and the fragments containing the Kdo-lipid A region (NA/LPS Bp1414 and NA/LPS BpA100) were isolated in the pellets. If TLC (solvent A ; see below) indicated incomplete deaminative cleavage, the pellet was treated with nitrous acid for a second time. The structure of NA/LPS Bp1414 is given in Fig. 1 . The distal pentasaccharide fragment (PeS) released from LPS Bp1414 during treatment with nitrous acid was isolated from the corresponding supernatant by chromatography on a Bio-Gel P2 column (Bio-Rad) eluted with water. Analyses of the PeS preparation by TLC (solvent B) showed no detectable contaminants.
Preparation of the PeS-BSA conjugate. The PeS isolated by nitrous acid deamination of LPS Bp1414 was directly coupled to BSA by reductive amination, as described by Roy et al. (1984) . Briefly, PeS (5 mg) was incubated for 48 h at 37 OC with BSA (10 mg) and sodium cyanoborohydride (20 pmol) in 0.2 M phosphate buffer (1 ml, pH 8). After neutralization with acetic acid, the solution was made up to 0-15 M NaCl and the conjugate was separated from uncoupled polysaccharide by Epitopes of B. pertztssis lipopolysaccharides chromatography on a Sephadex G-150 column. Elution was monitored by absorption at 220nm. The purified PeS-BSA conjugate (3.6 mg) contained 10% (w/w) PeS according to its heptose content. The structure of PeS-BSA is indicated in Fig Production of mAbs. The mouse which produced the highest titre of anti-LPS antibodies (detected after the second immunization) was selected for fusion. Three days after the last injection, the spleen cells were fused at a 10 : 1 ratio with SP2/0-Ag.14 myeloma cells, in 45 '/O (w/v) polyethylene glycol 1500, as described previously (Girard & Chaby, 1985) . Fusion products were cultured in a hypoxanthine/azaserine (50 pM : 10 pM) selection medium. Resulting colonies were tested for secretion of anti-LPS antibodies, and cloned by limiting dilution (Nowinsky et al., 1979). Clones were expanded as ascites by injection (5 x lo6 cells per mouse, i.p.) in BALB/c mice treated with pristane (0.5 ml, i.p.) two weeks previously.
ELISA. Sera and cell culture supernatants were assayed for anti-LPS or anti-BSA-conjugate antibodies by ELISA. The 96-well Immulon-A plates (Greiner Labortechnik) were coated with the antigen (100 p1 of 20 pg ml-' suspensions in 50 mM Tris/HCl buffer plus 20 mM MgCl!, pH 9.6). After overnight incubation at 20 "C with gentle stirring, the unbound antigen was washed away with 0.1 % Tween 20 in PBS (Tween buffer), and the plates were incubated for 1 h at 37 "C with 0.25 % (w/v) gelatin in the same buffer. The plates were rewashed with this solution and the sample of serum or culture supernatant (diluted in the same solution) added to each well. After incubation for 2 h at 37 "C, the plates were washed with the Tween buffer, and the peroxidase-labelled goat anti-mouse Ig reagent added. After incubation at 37 "C for 90 min, the plates were washed and The plates were dried again and saturated (1 h, 37 "C) with lowfat lyophilized milk (5%, w/v, in PBS). After three washings (5 min, 20 "C, with gentle stirring) in a washing buffer consisting of milk (5 %, W/V) and Tween 20 (0.1 Yo) in PBS, the plates were overlaid with one of the anti-LPS mAbs (undiluted cell culture supernatant of the corresponding hybridoma), incubated for 2 h at 37 OC with gentle shaking, and washed (three times, 5 min each) with the washing buffer. The plates were further incubated (1 h, 37 "C) with a peroxidase-labelled goat anti-mouse Ig reagent (1/1000 dilution), washed again, and developed (5-10 min, 20 "C) in a freshly prepared solution of diaminobenzidine (0.5 g F') in phosphate/citrate buffer (pH 5) containing sodium perborate (0.03 YO). The reaction was stopped by addition of acetic acid (0.1 ml AcOH in 20 ml of the substrate solution).
RESULTS

Antibody response to LPS in vivo
In a preliminary experiment, mice were injected, at 14 d (Fig. 2) show that a marked reactivity with the homologous LPS (Bp1414) was always obtained after the third injection, whereas none of the sera reacted with the variant strain A100 of B. pertussis, even after prolonged immunizations. Reactivities of sera with the B. broncbiseptica LPS were more variable: some sera (like those from mouse 1) reacted with this LPS, whereas others (like those from mouse 2) did not. These results show that although the three LPSs share some common substructures (Fig. l) , the immunogenicities of these substructures in mice are very different. with LPS were selected for this study (Table 1) . One clone (60.5) was produced with a mouse immunized with killed B. pertusis organisms, and two clones (PlP3 and D7) were obtained with mice immunized with the B. pertnssis LPS.
Production of hybridomas and ascitic fluids
Analyses of the isotypes of the mAbs prepared from ascitic fluids indicated that P1P3 and 60.5 are IgM, whereas D7 is an IgG3 (Table 1) .
Reactivity of the mAbs with unmodified Bordetella LPSs
The specificities of the three mAbs were analysed by their ability to interact with the LPSs from B. pertussis 1414, B. pertussis A1 00, B. broncbiseptica and B. parapertussis. Results obtained by ELISA (Fig. 3) showed clearcut differences in the specificities of these mAbs. All three mAbs reacted with LPS Bp1414 (Fig. 3a) , whereas only two of them (mAbs P1P3 and 60.5) interacted with the B. broncbiseptica LPS (Fig. 3c) , and only one (mAb P1P3) reacted with the B. parapertusis LPS (Fig. 3d) ; none of the three mAbs could recognize LPS BpAlOO (Fig. 3b) . These results clearly show that although the three mAbs interact with similar intensities with the LPS from strain 1414 of B. pertussis, they do so by binding to distinct epitopes.
Reactivity of the mAbs with rough-type LPSs
We established previously (Caroff e t al., 1990 ) that a rough-type LPS consisting of a pentasaccharide linked to lipid A (NA/LPS Bp1414) can be isolated from the nitrous-acid-treated LPS of B. pertassis 1414 (Fig. 1) . The reactivity of mAb P1P3 with NA/LPS Bp1414 was compared to its reactivity with untreated LPS Bp1414, and with rough-type LPSs from Salmonella (S. minnesota Rdl and S. ~phimnrizlm Rc). Reactivities were analysed by immunostaining the LPS bands after migration on TLC. The results (Fig. 4) show that mAb P1P3 reacted exclusively with the untreated LPS Bp1414, but reacted neither with NA/LPS Bp1414, nor with the rough LPSs from Salmonella. Identical results (not shown) were obtained with the two other mAbs, 60.5 and D7. These results demonstrate that the mAbs interact neither with the Kdo-lipid A region of the LPSs, nor with the four other sugar units which are vicinal to this region in LPS Bp1414 (GlcA-Hep-Hep, Glc).
Reactivity of mAb PIP3 with HF-treated LPS BpAlOO
The absence of reactivity of P1P3 with the short-chain lipopolysaccharides LPS BpXlOO (Fig. 3) and NA/LPS Bp1414 (Fig. 4) with longer chains. Another experiment (Fig. 5) , which confirmed this observation, provided an additional and unexpected result: after treatment of LPS BpAlOO with HF, the isolated material (HF/LPS-BpAlOO) was recognized by mAb PlP3, whereas the material obtained after sequential treatments with nitrous acid and H F (NA-HF/LPS BpA100) was no longer recognized by P1P3 (Fig. 5) . These results suggest (1) that the epitope recognized by P1P3 is released during nitrous acid treatment, and (2) that an HF-labile substituent modifies this epitope in the variant A100 strain of B. pertussis.
Reactivity of the mAbs with carbohydrate substructures coupled to BSA
The reactivities of the mAbs with distal carbohydrate substructures were analysed with conjugates consisting of the terminal monosaccharide GlcNAc, the disaccharide DiS, and the pentasaccharide PeS, covalently coupled to BSA. The reactivities of the three mAbs with these conjugates, and with unmodified BSA, were determined by ELISA. The results (Fig. 6) show that none of the mAbs reacted with BSA and DiS-BSA. Only one mAb (60.5) reacted with GlcNAc-BSA. The conjugate PeS-BSA, which carries the larger oligosaccharide substructure, was recognized by both P1P3 and 60.5. A significant but much lower reactivity was also observed with mAb D7.
DISCUSSION
The aim of the present study was to produce mAbs against distinct epitopes of the B. pertzlssis LPS that can potentially recognize the expression of atypical forms of (Fig. 3) . The only structure present in the two former and absent from the two latter LPSs is the distal trisaccharide GlcNAc -+ 2,3-NAcManA -+ FucN(Ac)Me. The reactivity of 60.5 with the GlchAc-BSA conjugate (Fig. 6 ) confirms this assumption and shows that the epitope recognized by mAb 60.5 consists of the terminal unit(s) of this distal trisaccharide (Fig. 7) . The reactivity of 60.5 with GlcNAc-BSA is, however, markedly lower than that obtained with the intact LAPS. This may suggest that the presence of the next carbohydrate unit (2,3-NAcManA) can optimize the reactivity, and thus may be partially involved in the recognized epitope.
The specificity of mAb D7 can also be deduced from the data in Figs 3 and 6. D7 reacts strongly with the B.pert~.ris 1414 LPS, reacts only at high concentrations with the B. bronchiseptica LPS, and does not react with the B. parapertussis LPS. This means that the presence of the 0-side chain, consisting of 2,3-NAcGalA repeating units, blocks the reactivity of D7 and thus modifies the epitope recognized by this mAb. The low reactivity of D7 with the PeS-BSA conjugate and with the B. bronchiseptica 1 2 3 shows, however, that the presence of the distal trisaccharide slightly enhances the reactivity of D7. Taken together, these results indicate that the epitope recognized by D7 is affected by the addition of the 0-side chain and that a portion of the distal trisaccharide could be involved in this epitope. This suggests therefore that this epitope may consist of the FucN(Ac)Me --+ GlcN disaccharide (Fig. 7) .
The third mAb, P1P3, reacted with a substructure shared by the LPSs of three conventional strains of Bordetella : B. pertussis 1414, B. bronchiseptica and B. parapertussis (Fig. 3) , thus indicating that the 0-chain is not involved in this reaction. The reactivity of P1P3 with the B. parapertussis LPS, and with the HF-treated LPS from B. pertussis A100 (HF/LPS-BpAlOO), shows that P1P3 does not react with the distal trisaccharide, which is absent from these two LPSs. Therefore, the epitope recognized by P1P3 is apparently located in the common ' core' structure ( Fig.  1) . The absence of reactivity of P1P3 with the rough-type fragment (NA/LPS Bp1414) isolated after nitrous acid cleavage (Fig. 4) indicated that the epitope is localized in the terminal sugar units of the core which are released during nitrous deamination (GlcN, GalNA, or Hep + GlcN). The interaction of P1P3 with the PeS-BSA conjugate (Fig. 6 ) demonstrated that the epitope is a part of the Hep -+ GlcN moiety, which is the only substructure present in both the PeS-BSA HF/LPS-BpAlOO. However, the epitope recognized by P1P3 cannot be the terminal heptose alone, since P1P3 does not react with the rough-type LPS from S. minnesota Rdl (Fig. 4) , which contains a terminal unsubstituted heptose unit. Therefore, we suggest that a region of the glucosamine unit to which the terminal heptose is attached also contributes to the epitope recognized by mAb P1P3. The carbon atoms 3,4, and 6 of this glucosamine unit could be involved in the epitope since this glucosamine substructure remains unmodified during the nitrous deamination of this residue, leading to 2,5-anhydromannose.
Whereas the inability of mAbs D7 and 60.5 to react with LPS BpAlOO can be easily ascribed to the absence of the corresponding epitopes, the inability of mAb P1P3 to react with this LPS (Fig. 3b) was unexpected. A similar absence of reactivity with LPS BpAlOO was also systematically observed with sera from mice immunized with LPS Bp1414 (Fig. 2) . This may suggest that the 'core' of the LPS from the variant strain A100 of B. pertussis could be different from that of the more conventional, vaccine strain 1414. However, in a previous study (Caroff e t al., 1990) , we established that the only detectable difference in the polysaccharide fragments isolated from LPS Bp1414 and LPS BpAlOO after HF treatment and mild acid hydrolysis was a loss of the distal trisaccharide in the latter, which suggests that the 'cores' of the HF-treated Epitopes of B. pertzlssis lipopolysaccharides LPSs are identical. This observation prompted us to examine the influence of H F treatment on the antigenicity of the LPS. We found that HF/LPS-BpAlOO was recognized by P1P3 (Fig. 5 ). This could indicate that the LPS of this variant strain of B. pertzlssis carries an HFlabile substituent in its core region. Structural analyses should soon shed light on this point.
Regarding the immunogenicity of B. pertassis LPS substructures, the observation that sera from some mice immunized with this LPS did not react with the B.
broncbiseptica LPS (Fig. 2) indicates that the epitopes recognized by P1P3 and 60.5 are less immunogenic than that detectable with D7. The observation that none of these sera could interact with the LPS from the B. pertzlssis A100 strain (Fig. 2) , and that we were unable to obtain a mAb that recognized the NA/LPS Bp1414, shows that the carbohydrate region proximal to lipid A is very poorly immunogenic.
The anti-B. pertzl.ui.r mAbs produced in this study, in addition to the anti-B. parapertassis and anti-B. broncbiseptica mAbs prepared previously (Le Blay e t a/., 1994), represent an efficient tool for routine identification of these organisms in clinical isolates, as well as for the detection of variations in the LPS components of these bacteria. It is noteworthy that these clinical applications of the mAbs should be much easier if the conclusions drawn from the present study, in which experiments were carried out with isolated LPSs, could be extended to LPS in its natural environment, where it is exposed on the surface of intact organisms. It is clear that this situation can modify the accessibility of certain LPS epitopes, and thus limit the use of the corresponding antibodies. Experiments designed to analyse the interactions of the mAbs with intact organisms are now planned.
